USE OF RILUZOLE ORAL DISINTEGRATING TABLETS FOR TREATING DISEASES
Disclosed are methods of treating a disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof, in the form of an oral solid molded fast-dispersing dosage form. Pharmaceutical compositions and kits are also disclosed.
1 - 10 . (canceled)
11 . A pharmaceutical composition comprising 50-70% riluzole, 15-25 weight % gelatin, 10-20 weight % mannitol, and 0.1-2 weight % docusate sodium, based on the total weight of the pharmaceutical composition, in the form of an oral solid molded fast-dispersing dosage form in order to provide an AUC 0-t of from about 80-125% of about 740000 hr*pg/mL, wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 50 to 90% of the dosage of riluzole in a conventional tablet in order to provide an AUC 0-t . of about 740000 hr*pg/mL.
12 . The pharmaceutical composition of claim 11 , wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 70 to 85% of the dosage of riluzole in a conventional tablet in order to provide an AUC 0-t . of about 740000 hr*pg/mL.
13 . The pharmaceutical composition of claim 11 , wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 80% of the dosage of riluzole in a conventional tablet in order to provide an AUC 0-t . of about 740000 hr*pg/mL.
14 . The pharmaceutical composition of claim 11 , wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 40 mg.
15 . (canceled)
16 . (canceled)
17 . A kit for treating a disease in a patient, the kit comprising:
(a) a pharmaceutical composition comprising 50-70% riluzole, 15-25 weight % gelatin, 10-20 weight % mannitol, and 0.1-2 weight % docusate sodium, based on the total weight of the pharmaceutical composition in the form of an oral solid molded fast dispersing tablet; and
(b) instructions for administering the pharmaceutical composition;
wherein the pharmaceutical composition provides an AUC 0-t of from about 80-125% of 740000 (hr*pg/mL).
18 . The kit of claim 17 , wherein the oral solid molded fast dispersing tablet provides an AUC 0-t . of about 740000 hr*pg/mL.
19 . The pharmaceutical composition of claim 17 , wherein the oral solid molded fast dispersing tablet provides an AUC 0-t . of about 740000 hr*pg/mL.
20 . The pharmaceutical composition of claim 17 , wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 40 mg.